title: Therapeutic approaches to patients with hypereosinophilic syndromes.
abstract: Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders that range from asymptomatic eosinophilia > 1,500/mL to aggressive disease complicated by life-threatening end organ involvement, including endomyocardial fibrosis and thromboembolism. To complicate matters further, similar clinical manifestations can occur in the setting of marked eosinophilia due to helminth infection, drug hypersensitivity, and other causes. In the past, therapy was guided only by the exclusion of these secondary causes of eosinophilia and the severity of the clinical manifestations. More recently, the availability of novel targeted therapies and a better understanding of the etiologies of some subtypes of HES have necessitated a more structured approach.
authors.affiliation: Institute of Pharmacology, University of Bern, Bern, Switzerland.
authors.forename: Hans-Uwe
authors.initials: HU
authors.lastname: Simon
authors.forename: Amy
authors.initials: A
authors.lastname: Klion
mesh_terms: D004342:Drug Hypersensitivity / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D004719:Endomyocardial Fibrosis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D006373:Helminthiasis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D013923:Thromboembolism / Q000473:pathology / Q000503:physiopathology / Q000628:therapy